Volume 30, Issue 3 (6-2022)                   JSSU 2022, 30(3): 4633-4641 | Back to browse issues page


XML Persian Abstract Print


Abstract:   (681 Views)
Introduction: Meningioma is a benign tumor of the brain, which shows a good response to treatment, surgery and benign pathology, but there is a possibility of recurrence. Therefore, the present study was conducted to investigate the relationship between recurrent meningioma risk factors and the rate of meningioma recurrence in Yazd City.
Methods: This descriptive-analytical study was performed on all the patients who have surgery for meningioma in Shahid Rahnemoun and Mortaz Hospitals in Yazd City for 10 years. Patient's information, including age, sex, size, grade, diseases and bone changes were extracted from the patients' records. After determining the recurrence status of the disease, information was entered into SPSS version 16 software for Chi-square, Anova and T-test.
Results: The most common meningioma was in the age group of 50 to 70 years. In this study, out of 300 patients with meningioma who underwent surgery, 50 (16.7%) had a recurrence of the disease. The recurrence rate was significantly associated with meningioma size, disease grade, and radiotherapy and diabetes (P <0.05). The recurrence rate in this study decreased with the increasing age of the patients.
Conclusion: According to the results, considering factors such as age, disease grade, tumor size, radiotherapy and diabetes, which are important predictors of disease recurrence, in managing meningioma patients after surgery and identifying high-risk individuals for disease recurrence are helpful. In the following, due to the involvement of effective factors in the disease, more extensive and retrospective studies are recommended.
 
Full-Text [PDF 658 kb]   (323 Downloads)    
Type of Study: Original article | Subject: Neurology
Received: 2021/06/22 | Accepted: 2021/08/29 | Published: 2022/06/5

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.